Načítá se...

GEN-06 CLINICAL COURSE AFTER TUMOR RECURRENCE OF MGMT HYPERMETHYLATED GLIOBLASTOMA

MGMT methylation in glioblastoma is a biomarker for determining treatment responsiveness and predicting prognosis. We analyzed whether there were differences in the prognosis between glioblastoma with MGMT hypermethylation and other glioblastomas after tumor recurrence. We enrolled 184 patients who...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neurooncol Adv
Hlavní autoři: Adachi, Junichi, Shirahata, Mitsuaki, Suzuki, Tomonari, Mishima, Kazuhiko, Fujimaki, Takamitsu, Nishikawa, Ryo
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2019
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7213324/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdz039.035
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!